PT BUNDAMEDIK TBK |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 310 IDR | +0.65% |
|
+1.31% | -4.91% |
| Mar. 31 | PT Bundamedik Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | PT Bundamedik Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,140,835 | 3,544,607 | 2,804,714 | 2,667,059 | - | - |
| Enterprise Value (EV) 1 | 7,140,835 | 3,544,607 | 2,804,714 | 2,667,059 | 2,667,059 | 2,667,059 |
| P/E ratio | - | - | - | - | - | - |
| Yield | 0.31% | - | - | 0.03% | 0.42% | 0.58% |
| Capitalization / Revenue | 4.17 x | 2.14 x | 1.88 x | 1.59 x | 1.41 x | 1.28 x |
| EV / Revenue | 4.17 x | 2.14 x | 1.88 x | 1.59 x | 1.41 x | 1.28 x |
| EV / EBITDA | 15.8 x | 11.6 x | 15.1 x | 9.33 x | 7.58 x | 7.07 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 4.58 x | - | - | 1.61 x | 1.51 x | 1.59 x |
| Nbr of stocks (in thousands) | 8,603,416 | 8,603,416 | 8,603,416 | 8,603,416 | - | - |
| Reference price 2 | 830.0 | 412.0 | 326.0 | 310.0 | 310.0 | 310.0 |
| Announcement Date | 4/11/22 | 4/3/23 | 3/31/24 | - | - | - |
1IDR in Million2IDR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,711 | 1,659 | 1,488 | 1,675 | 1,885 | 2,086 |
| EBITDA 1 | - | 451.3 | 304.7 | 185.3 | 286 | 352 | 377 |
| EBIT 1 | - | 393.5 | 215.1 | 90.55 | 189 | 250 | 271 |
| Operating Margin | - | 23% | 12.97% | 6.08% | 11.28% | 13.26% | 12.99% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income | 88.79 | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| EPS | 41,548 | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 2.557 | - | - | 0.1000 | 1.300 | 1.800 |
| Announcement Date | 7/6/21 | 4/11/22 | 4/3/23 | 3/31/24 | - | - | - |
1IDR in Billions2IDR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 17% | 4.62% | - | 4.2% | 6.4% | 6.9% |
| ROA (Net income/ Total Assets) | - | 8.88% | - | - | 2.2% | 3.4% | 3.8% |
| Assets | - | - | - | - | - | - | - |
| Book Value Per Share 1 | - | 181.0 | - | - | 193.0 | 205.0 | 195.0 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 2 | - | 228 | - | - | 134 | 94 | 104 |
| Capex / Sales | - | 13.33% | - | - | 8% | 4.99% | 4.99% |
| Announcement Date | 7/6/21 | 4/11/22 | 4/3/23 | 3/31/24 | - | - | - |
1IDR2IDR in Billions
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
310
IDR
Average target price
330
IDR
Spread / Average Target
+6.45%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.91% | 166M | |
| +18.92% | 84.31B | |
| -29.48% | 69.9B | |
| +9.65% | 29.06B | |
| +1.57% | 17.01B | |
| -9.30% | 17.38B | |
| +0.20% | 15.35B | |
| +5.25% | 12.91B | |
| +68.96% | 12.47B | |
| -2.48% | 11.9B |
- Stock Market
- Equities
- BMHS Stock
- Financials PT Bundamedik Tbk